Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock Position Lifted by Truist Financial Corp

Truist Financial Corp raised its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 136.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,398 shares of the biopharmaceutical company's stock after purchasing an additional 2,539 shares during the quarter. Truist Financial Corp's holdings in Alnylam Pharmaceuticals were worth $1,035,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of ALNY. Jennison Associates LLC purchased a new position in Alnylam Pharmaceuticals in the fourth quarter valued at about $61,160,000. Strategic Financial Concepts LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at about $41,529,000. Eventide Asset Management LLC raised its holdings in shares of Alnylam Pharmaceuticals by 157.9% during the 3rd quarter. Eventide Asset Management LLC now owns 224,333 shares of the biopharmaceutical company's stock valued at $61,698,000 after buying an additional 137,333 shares during the period. Los Angeles Capital Management LLC lifted its position in Alnylam Pharmaceuticals by 11,433.4% during the 3rd quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company's stock worth $37,684,000 after acquiring an additional 135,829 shares in the last quarter. Finally, Telemark Asset Management LLC purchased a new position in Alnylam Pharmaceuticals in the 3rd quarter worth approximately $27,503,000. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total value of $362,246.40. Following the completion of the sale, the executive vice president now directly owns 12,881 shares in the company, valued at $3,240,344.36. This represents a 10.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CMO Pushkal Garg sold 52,592 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, January 27th. The shares were sold at an average price of $285.00, for a total value of $14,988,720.00. Following the transaction, the chief marketing officer now owns 11,989 shares in the company, valued at approximately $3,416,865. This trade represents a 81.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 72,986 shares of company stock valued at $20,397,849. Company insiders own 1.50% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on ALNY shares. Piper Sandler restated an "overweight" rating and issued a $296.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. HC Wainwright raised their target price on Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the company a "buy" rating in a research note on Monday, February 24th. StockNews.com cut Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, January 9th. Wolfe Research downgraded Alnylam Pharmaceuticals from a "peer perform" rating to an "underperform" rating in a report on Tuesday, November 12th. Finally, Scotiabank dropped their price objective on Alnylam Pharmaceuticals from $310.00 to $300.00 and set a "sector outperform" rating on the stock in a report on Friday, February 14th. One analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $304.26.

Alnylam Pharmaceuticals Stock Performance

ALNY stock traded up $6.30 on Wednesday, reaching $249.23. The company's stock had a trading volume of 645,250 shares, compared to its average volume of 792,183. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The company has a market capitalization of $32.26 billion, a P/E ratio of -114.85 and a beta of 0.35. The firm has a fifty day moving average of $254.34 and a two-hundred day moving average of $261.90.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.